Free tool
FAERS Monitor: Bonjesta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209661 or its brand name (Bonjesta, Doxylamine Succinate, Pyridoxine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
153
Serious
71
46% of reports
Hospitalization
36
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- maternal exposure during pregnancy25
- nausea17
- drug ineffective16
- exposure during pregnancy16
- off label use13
- abortion spontaneous12
- product use in unapproved indication10
- serotonin syndrome10
- somnolence10
- vomiting10
- drug ineffective for unapproved indication9
- foetal exposure during pregnancy8
- anxiety6
- fatigue6
- vision blurred6
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 22 |
| 2019 | 28 |
| 2020 | 12 |
| 2021 | 16 |
| 2022 | 21 |
| 2023 | 16 |
| 2024 | 15 |
| 2025 | 13 |
| 2026 | 10 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,006 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| serotonin syndromeSignal | 10 | 71.6 | 39.3 | 628 |
| abortion spontaneousSignal | 12 | 41.2 | 23.9 | 432 |
| maternal exposure during pregnancySignal | 25 | 38.6 | 26.9 | 881 |
| exposure during pregnancySignal | 16 | 35.4 | 22.3 | 502 |
| drug ineffective for unapproved indicationSignal | 9 | 22.5 | 12.0 | 165 |
| foetal exposure during pregnancySignal | 8 | 13.5 | 6.9 | 81 |
| somnolenceSignal | 10 | 6.8 | 3.7 | 45 |
| vision blurredSignal | 6 | 6.0 | 2.7 | 20 |
| product use in unapproved indicationSignal | 10 | 5.5 | 3.0 | 33 |
| nauseaSignal | 17 | 3.0 | 1.9 | 21 |
| vomitingSignal | 10 | 2.9 | 1.6 | 11 |
| anxietySignal | 6 | 2.9 | 1.3 | 6 |
| off label useSignal | 13 | 2.0 | 1.2 | 6 |
| drug ineffective | 16 | 1.7 | 1.0 | 4 |
| fatigue | 6 | 1.1 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.